KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables - Other (2021 - 2025)

Historic Receivables - Other for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to $21.9 million.

  • Recursion Pharmaceuticals' Receivables - Other rose 87161.86% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year increase of 87161.86%. This contributed to the annual value of $7.9 million for FY2024, which is 15533.29% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Receivables - Other is $21.9 million, which was up 87161.86% from $5.9 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Receivables - Other high stood at $49.2 million for Q4 2024, and its period low was $2.1 million during Q1 2023.
  • Its 5-year average for Receivables - Other is $11.5 million, with a median of $5.9 million in 2025.
  • Its Receivables - Other has fluctuated over the past 5 years, first tumbled by 8189.74% in 2023, then soared by 167468.26% in 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Receivables - Other (Quarter) stood at $9.1 million in 2021, then tumbled by 69.6% to $2.8 million in 2022, then rose by 12.39% to $3.1 million in 2023, then skyrocketed by 1489.08% to $49.2 million in 2024, then tumbled by 55.44% to $21.9 million in 2025.
  • Its Receivables - Other stands at $21.9 million for Q3 2025, versus $5.9 million for Q2 2025 and $46.1 million for Q1 2025.